|
Volumn 314, Issue 18, 2015, Pages 1909-1910
|
Predicting the overuse of PCSK-9 inhibitors
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALIROCUMAB;
ANTILIPEMIC AGENT;
EVOLOCUMAB;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9;
PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR;
SUBTILISIN;
UNCLASSIFIED DRUG;
BIOLOGICAL MARKER;
MONOCLONAL ANTIBODY;
PCSK9 PROTEIN, HUMAN;
SERINE PROTEINASE;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR MORTALITY;
CATARACT;
COGNITIVE DEFECT;
CORONARY ARTERY ATHEROSCLEROSIS;
DRUG RECHALLENGE;
DRUG SUBSTITUTION;
DRUG TREATMENT FAILURE;
DRUG WITHDRAWAL;
FAMILIAL HYPERCHOLESTEROLEMIA;
HUMAN;
HYPERGLYCEMIA;
HYPERTRANSAMINASEMIA;
HYPOGONADISM;
LOW DRUG DOSE;
MEDICATION COMPLIANCE;
MUSCLE DISEASE;
NEOPLASM;
NEUROPATHY;
NOTE;
PATIENT COMPLIANCE;
PREDICTION;
PRIORITY JOURNAL;
RHABDOMYOLYSIS;
RISK REDUCTION;
SYSTEMIC LUPUS ERYTHEMATOSUS;
ANTAGONISTS AND INHIBITORS;
BLOOD;
CARDIOVASCULAR DISEASES;
FORECASTING;
REFERENCE VALUE;
TREATMENT FAILURE;
TRENDS;
ANTIBODIES, MONOCLONAL;
BIOMARKERS;
CARDIOVASCULAR DISEASES;
CHOLESTEROL, LDL;
DRUG SUBSTITUTION;
FORECASTING;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
MEDICATION ADHERENCE;
PROPROTEIN CONVERTASES;
REFERENCE VALUES;
SERINE ENDOPEPTIDASES;
TREATMENT FAILURE;
|
EID: 84946811245
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2015.13414 Document Type: Note |
Times cited : (8)
|
References (8)
|